IBB vs SQQQ

iShares Biotechnology ETF vs ProShares UltraPro Short QQQ

Quick take
  • IBB has the lower expense ratio at 0.44% vs 0.95% for SQQQ.
  • SQQQ pays a higher dividend yield (11.03%).

Side-by-side metrics

MetricIBBSQQQ
Expense ratio
Annual fee. Lower is better.
0.44%0.95%
Dividend yield
Trailing 12-month yield.
0.22%11.03%
AUM
Assets under management — bigger funds are typically more liquid.
$9.09B$1.99B
YTD return
16.44%-40.07%
1-year return
3-year return
Annualized.
5-year return
Annualized.
10-year return
Annualized.
Beta (3Y)
Volatility relative to the market. Closer to 1 = market-like.
0.69-3.20
P/E ratio
24.89
Last price
$197.34$38.10
Inception
Issuer
iSharesProShares

IBB top holdings

Top holdings · IBB
VRTXVertex Pharmaceuticals Inc8.07%
AMGNAmgen Inc7.82%
GILDGilead Sciences Inc6.83%
REGNRegeneron Pharmaceuticals Inc4.90%
ARGXargenx SE ADR3.75%
ALNYAlnylam Pharmaceuticals Inc3.12%
NTRANatera Inc2.89%
RVMDRevolution Medicines Inc Ordinary Shares2.78%
BIIBBiogen Inc2.46%
ILMNIllumina Inc2.07%
Sector breakdown · IBB
Healthcare100.0%

SQQQ top holdings

Holdings data unavailable for SQQQ.

About IBB

IBB (iShares Biotechnology ETF) is NASDAQ biotech and pharmaceutical companies. Managed by iShares, the fund carries $9.1B in assets under management, an expense ratio of 0.44%, a dividend yield of 0.22%. Its largest holding is Vertex Pharmaceuticals Inc (VRTX), which represents 8.1% of the portfolio. Healthcare is the fund's largest sector exposure at 100.0%.

About SQQQ

SQQQ (ProShares UltraPro Short QQQ) is 3x inverse daily performance of the Nasdaq-100. Managed by ProShares, the fund carries $2.0B in assets under management, an expense ratio of 0.95%, a dividend yield of 11.03%.